Drug Patents Expiring in 2030

1. Drug name - ABILIFY MYCITE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8847766 OTSUKA Pharma-informatics system Mar, 2030

(7 years from now)

US8545402 OTSUKA Highly reliable ingestible event markers and methods for using the same Apr, 2030

(7 years from now)

US8114021 OTSUKA Body-associated receiver and method Jun, 2030

(7 years from now)

US9941931 OTSUKA System for supply chain management Nov, 2030

(8 years from now)

US8961412 OTSUKA In-body device with virtual dipole signal amplification Nov, 2030

(8 years from now)

US8258962 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same Nov, 2030

(8 years from now)

US8547248 OTSUKA Implantable zero-wire communications system Dec, 2030

(8 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

2. Drug name - ACETAMINOPHEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741959 FRESENIUS KABI USA Paracetamol for parenteral administration Apr, 2030

(7 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM/100ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription

3. Drug name - AKYNZEO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US9943515 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US8951969 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US8623826 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Dec, 2030

(8 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
300MG;EQ 0.5MG BASE CAPSULE;ORAL Prescription

4. Drug name - AKYNZEO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Nov, 2030

(8 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting Dec, 2030

(8 years from now)

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL POWDER;INTRAVENOUS Prescription
EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

5. Drug name - ALECENSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9440922 HOFFMANN-LA ROCHE Tetracyclic compound Jun, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE CAPSULE;ORAL Prescription

6. Drug name - ALUNBRIG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012462 TAKEDA PHARMS USA Phosphorous derivatives as kinase inhibitors
Jul, 2030

(7 years from now)

Drugs and Companies using BRIGATINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription
180MG TABLET;ORAL Prescription

7. Drug name - AMONDYS 45

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9228187 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(8 years from now)

US10287586 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(8 years from now)

CN105838714A SAREPTA THERAPS INC Antisense Molecule And Method For Treating Disease.
Nov, 2030

(8 years from now)

CN105838714B SAREPTA THERAPS INC Antisense Molecules And Method For Treating Disease
Nov, 2030

(8 years from now)

IN347912B SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

IN201204202P4 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

EP2499249B1 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

EP2499249A4 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

EP2499249A1 SAREPTA THERAPS INC Antisense Molecules And Methods For Treating Pathologies
Nov, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10781450 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies Nov, 2030

(8 years from now)

US9758783 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies Nov, 2030

(8 years from now)

Drugs and Companies using CASIMERSEN ingredient

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production; Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping; treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

8. Drug name - AMZEEQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10137200 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses Oct, 2030

(8 years from now)

US8865139 JOURNEY Topical tetracycline compositions Oct, 2030

(8 years from now)

US9675700 JOURNEY Topical tetracycline compositions Oct, 2030

(8 years from now)

US8992896 JOURNEY Topical tetracycline compositions Oct, 2030

(8 years from now)

US10086080 JOURNEY Topical tetracycline compositions Oct, 2030

(8 years from now)

US10213512 JOURNEY Topical tetracycline compositions Oct, 2030

(8 years from now)

US10517882 JOURNEY Method for healing of an infected acne lesion without scarring Oct, 2030

(8 years from now)

US10821187 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof Oct, 2030

(8 years from now)

US10265404 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof Oct, 2030

(8 years from now)

US8945516 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses Oct, 2030

(8 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 4% BASE AEROSOL, FOAM;TOPICAL Prescription

9. Drug name - ANJESO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253478 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions May, 2030

(7 years from now)

US9974746 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions May, 2030

(7 years from now)

US10709713 BAUDAX Nanoparticulate meloxicam formulations May, 2030

(7 years from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
30MG/ML (30MG/ML) SOLUTION;INTRAVENOUS Prescription

10. Drug name - ANORO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser Oct, 2030

(8 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist Nov, 2030

(8 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist Nov, 2030

(8 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

11. Drug name - APADAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9132125 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(7 years from now)

US9549923 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
Jul, 2030

(7 years from now)

US8748413 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(7 years from now)

CN102480959A KVK TECH INC Benzoic Acid Conjugate Of Hydrocodone, Benzoic Acid Derivative Conjugate, Heteroaryl Carboxylic Acid Conjugate And Predrug, Preparation Method And Usage Thereof
Jul, 2030

(7 years from now)

CN102480959B KVK TECH INC Benzoic Acid Conjugate Of Hydrocodone, Benzoic Acid Derivative Conjugate And Heteroaryl Carboxylic Acid Conjugates And Prodrugs Thereof, Preparation Method And Use Thereof
Jul, 2030

(7 years from now)

IN201110011P1 KVK TECH INC Benzoic Acid, Benzoic Acid Derivatives And Heteroaryl Carboxylic Acid Conjugates Of Hydrocodone, Prodrugs, Methods Of Making And Use Thereof
Jul, 2030

(7 years from now)

IN293793B KVK TECH INC Benzoic Acid, Benzoic Acid Derivatives And Heteroaryl Carboxylic Acid Conjugates Of Hydrocodone, Prodrugs, Methods Of Making And Use Thereof
Jul, 2030

(7 years from now)

EP2448407B1 KVK TECH INC Benzoic Acid, Benzoic Acid Derivatives And Heteroaryl Carboxylic Acid Conjugates Of Hydrocodone, Prodrugs, Methods Of Making And Use Thereof
Jul, 2030

(7 years from now)

EP2448407A1 KVK TECH INC Benzoic Acid, Benzoic Acid Derivatives And Heteroaryl Carboxylic Acid Conjugates Of Hydrocodone, Prodrugs, Methods Of Making And Use Thereof
Jul, 2030

(7 years from now)

EP2448407A4 KVK TECH INC Benzoic Acid, Benzoic Acid Derivatives And Heteroaryl Carboxylic Acid Conjugates Of Hydrocodone, Prodrugs, Methods Of Making And Use Thereof
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828978 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof Jul, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
325MG;EQ 4.08MG BASE TABLET;ORAL Prescription
325MG;EQ 6.12MG BASE TABLET;ORAL Prescription
325MG;EQ 8.16MG BASE TABLET;ORAL Prescription

12. Drug name - APRISO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865688 VALEANT PHARMS INTL Compositions and methods for treatment of bowel diseases with granulated mesalamine May, 2030

(7 years from now)

Drugs and Companies using MESALAMINE ingredient

Treatment: For the maintenance of remission of ulcerative colitis

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
375MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

13. Drug name - APTIOM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8372431 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate Apr, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription
400MG TABLET;ORAL Prescription
600MG TABLET;ORAL Prescription
800MG TABLET;ORAL Prescription

14. Drug name - ARISTADA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(8 years from now)

EP2445502B1 ALKERMES INC Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders
Jun, 2030

(7 years from now)

EP2445502A1 ALKERMES INC Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders
Jun, 2030

(7 years from now)

EP2445343A1 ALKERMES INC Prodrugs Of Nh-Acidic Compounds
Jun, 2030

(7 years from now)

EP2445343B1 ALKERMES INC Prodrugs Of Nh-Acidic Compounds
Jun, 2030

(7 years from now)

EP2445502A4 ALKERMES INC Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders
Jun, 2030

(7 years from now)

EP2445343A4 ALKERMES INC Prodrugs Of Nh-Acidic Compounds
Jun, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders Jun, 2030

(7 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
441MG/1.6ML (275.63MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
662MG/2.4ML (275.83MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
882MG/3.2ML (275.63MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
1064MG/3.9ML (272.82MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

15. Drug name - ARISTADA INITIO KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(8 years from now)

EP2445502B1 ALKERMES INC Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders
Jun, 2030

(7 years from now)

EP2445502A1 ALKERMES INC Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders
Jun, 2030

(7 years from now)

EP2445343A1 ALKERMES INC Prodrugs Of Nh-Acidic Compounds
Jun, 2030

(7 years from now)

EP2445343B1 ALKERMES INC Prodrugs Of Nh-Acidic Compounds
Jun, 2030

(7 years from now)

EP2445502A4 ALKERMES INC Heterocyclic Compounds For The Treatment Of Neurological And Psychological Disorders
Jun, 2030

(7 years from now)

EP2445343A4 ALKERMES INC Prodrugs Of Nh-Acidic Compounds
Jun, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders Jun, 2030

(7 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
675MG/2.4ML SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

16. Drug name - ARNUITY ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser Oct, 2030

(8 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
0.05MG/INH POWDER;INHALATION Prescription
0.1MG/INH POWDER;INHALATION Prescription
0.2MG/INH POWDER;INHALATION Prescription

17. Drug name - ATROVENT HFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8474447 BOEHRINGER INGELHEIM Inhaler device Jan, 2030

(7 years from now)

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.021MG/INH AEROSOL, METERED;INHALATION Prescription

18. Drug name - AUBAGIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802735 SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability Sep, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
7MG TABLET;ORAL Prescription
14MG TABLET;ORAL Prescription

19. Drug name - AURYXIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10300039 KERYX BIOPHARMS Ferric citrate dosage forms Jul, 2030

(7 years from now)

US9387191 KERYX BIOPHARMS Ferric citrate dosage forms Jul, 2030

(7 years from now)

Drugs and Companies using FERRIC CITRATE ingredient

Treatment: Control of serum phosphorus levels

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 210MG IRON TABLET;ORAL Prescription

20. Drug name - AVYCAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835455 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt Oct, 2030

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5GM BASE;2GM/VIAL POWDER;INTRAVENOUS Prescription

21. Drug name - BESIVANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8604020 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals Mar, 2030

(7 years from now)

US8415342 BAUSCH AND LOMB Besifloxacin ophthalmic composition for the treatment or control of infection Nov, 2030

(8 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.6% BASE SUSPENSION/DROPS;OPHTHALMIC Prescription

22. Drug name - BEVESPI AEROSPHERE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703806 ASTRAZENECA Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents May, 2030

(7 years from now)

US8808713 ASTRAZENECA Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems May, 2030

(7 years from now)

US10716753 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems May, 2030

(7 years from now)

US9463161 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems May, 2030

(7 years from now)

US9415009 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents May, 2030

(7 years from now)

US8324266 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents May, 2030

(7 years from now)

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.0048MG/INH;0.0090MG/INH AEROSOL, METERED;INHALATION Prescription

23. Drug name - BEVYXXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8987463 PORTOLA PHARMS INC Methods of synthesizing factor Xa inhibitors Dec, 2030

(8 years from now)

Drugs and Companies using BETRIXABAN ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Discontinued
80MG CAPSULE;ORAL Discontinued

24. Drug name - BEYAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid Feb, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
3MG,N/A;0.02MG,N/A;0.451MG,0.451MG TABLET;ORAL Prescription

25. Drug name - BRAFTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8541575 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Feb, 2030

(7 years from now)

US9593099 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

CN102725283A ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

CN103896921A ARRAY BIOPHARMA INC Compound And Composition As A Protein Kinase Inhibitor
Aug, 2030

(7 years from now)

CN102725283B ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

CN103896921B ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

IN201202469P1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

IN303554B ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2727918B1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2727918A1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2470526B1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

EP2470526A1 ARRAY BIOPHARMA INC Compounds And Compositions As Protein Kinase Inhibitors
Aug, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9850230 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

Drugs and Companies using ENCORAFENIB ingredient

Treatment: Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Treatment of melanoma with a braf mutation; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued
75MG CAPSULE;ORAL Prescription

26. Drug name - BREO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXO GRP LTD Manifold for use in medicament dispenser Mar, 2030

(7 years from now)

US8746242 GLAXO GRP LTD Medicament dispenser Oct, 2030

(8 years from now)

More Information on Dosage
Strength Dosage Availability
0.1MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription
0.2MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

27. Drug name - BREXAFEMME

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188085 SCYNEXIS Antifungal agents
Aug, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription

28. Drug name - BREZTRI AEROSPHERE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415009 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents May, 2030

(7 years from now)

US10716753 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems May, 2030

(7 years from now)

US8703806 ASTRAZENECA AB Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents May, 2030

(7 years from now)

US8808713 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems May, 2030

(7 years from now)

US8324266 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents May, 2030

(7 years from now)

US9463161 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems May, 2030

(7 years from now)

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.16MG/INH;0.0048MG/INH;0.009MG/INH AEROSOL, METERED;INHALATION Prescription

29. Drug name - BRILINTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8425934 ASTRAZENECA Pharmaceutical compositions Apr, 2030

(7 years from now)

Drugs and Companies using TICAGRELOR ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription

30. Drug name - BRIVIACT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729653 UCB INC Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives Apr, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
25MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
75MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

31. Drug name - BYDUREON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8998876 ASTRAZENECA AB Ampoule comprising an ampoule holder Jan, 2030

(7 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder Jan, 2030

(7 years from now)

US8998876

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder Jul, 2030

(7 years from now)

US8721615

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder Jul, 2030

(7 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued
2MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued

32. Drug name - BYDUREON BCISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895033 ASTRAZENECA AB Sustained release formulations using non-aqueous carriers Oct, 2030

(8 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; stimulating insulin release in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; delaying gastric emptying in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.85ML (2MG/0.85ML) SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

33. Drug name - CABOMETYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11091439 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(7 years from now)

US8877776 EXELIXIS INC (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(8 years from now)

EP2387563B2 EXELIXIS INC Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

EP2387563B1 EXELIXIS INC Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

EP2387563A1 EXELIXIS INC Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11098015 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer Jan, 2030

(7 years from now)

US11091440 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer Jan, 2030

(7 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; treatment of renal cell carcinoma; treatment of advanced renal cell carcinoma; treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription
EQ 60MG BASE TABLET;ORAL Prescription

34. Drug name - CALDOLOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9012508 CUMBERLAND PHARMS Administration of intravenous ibuprofen Sep, 2030

(7 years from now)

Drugs and Companies using IBUPROFEN ingredient

Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
400MG/4ML (100MG/ML) SOLUTION;INTRAVENOUS Discontinued
800MG/8ML (100MG/ML) SOLUTION;INTRAVENOUS Prescription
800MG/200ML (4MG/ML) SOLUTION;INTRAVENOUS Prescription

35. Drug name - CHILDREN'S ALLEGRA ALLERGY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8933097 CHATTEM SANOFI Fexofenadine suspension formulation Aug, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
30MG/5ML SUSPENSION;ORAL Discontinued

36. Drug name - COMBIVENT RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism Oct, 2030

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE/INH;0.02MG/INH SPRAY, METERED;INHALATION Prescription

37. Drug name - COMETRIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11091439 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(7 years from now)

US8877776 EXELIXIS (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(8 years from now)

EP2387563B2 EXELIXIS Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

EP2387563B1 EXELIXIS Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

EP2387563A1 EXELIXIS Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091440 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer Jan, 2030

(7 years from now)

US11098015 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer Jan, 2030

(7 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: Method of treating medullary thyroid cancer

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

38. Drug name - CONSENSI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408837 PURPLE BIOTECH Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs Feb, 2030

(7 years from now)

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE;200MG TABLET;ORAL Discontinued
EQ 5MG BASE;200MG TABLET;ORAL Discontinued
EQ 10MG BASE;200MG TABLET;ORAL Discontinued

39. Drug name - CONTRAVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8916195 NALPROPION Sustained release formulation of naltrexone Feb, 2030

(7 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
90MG;8MG TABLET, EXTENDED RELEASE;ORAL Prescription

40. Drug name - COPIKTRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8193182 SECURA Substituted isoquinolin-1(2H)-ones, and methods of use thereof
Feb, 2030

(7 years from now)

CN102711767B SECURA Some Real Chemistry, Composition And Method
Jul, 2030

(7 years from now)

CN109912599A SECURA Chemical Entities, Compositions And Methods
Jul, 2030

(7 years from now)

CN109912599B SECURA Chemical Entities, Compositions And Methods
Jul, 2030

(7 years from now)

CN102711767A SECURA Certain Chemical Entities, Compositions And Method
Jul, 2030

(7 years from now)

CN106188059A SECURA Some Real Chemistry, Composition And Method
Jul, 2030

(7 years from now)

CN106188059B SECURA Certain Chemical Entities, Compositions And Method
Jul, 2030

(7 years from now)

IN201200943P1 SECURA Certain Chemical Entities, Compositions And Methods
Jul, 2030

(7 years from now)

EP3150609A1 SECURA Process For Preparing Certain Chemical Entities
Jul, 2030

(7 years from now)

EP2918589A1 SECURA Adenine Derivative As Pi3K Inhibitor
Jul, 2030

(7 years from now)

EP3441392A1 SECURA A Pharmaceutical Composition For Oral Administration
Jul, 2030

(7 years from now)

EP3150609B1 SECURA Process For Preparing Certain Chemical Entities
Jul, 2030

(7 years from now)

EP2918589B1 SECURA Adenine Derivative As Pi3K Inhibitor
Jul, 2030

(7 years from now)

EP3441392B1 SECURA A Pharmaceutical Composition For Oral Administration
Jul, 2030

(7 years from now)

EP2456444B1 SECURA Adenine Derivative As Pi3K Inhibitor
Jul, 2030

(7 years from now)

EP2456444A4 SECURA Certain Chemical Entities, Compositions And Methods
Jul, 2030

(7 years from now)

EP2456444A1 SECURA Adenine Derivative As Pi3K Inhibitor
Jul, 2030

(7 years from now)

Drugs and Companies using DUVELISIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG CAPSULE;ORAL Prescription
25MG CAPSULE;ORAL Prescription

41. Drug name - CUBICIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods Nov, 2030

(8 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
250MG/VIAL POWDER;INTRAVENOUS Discontinued
500MG/VIAL POWDER;INTRAVENOUS Prescription

42. Drug name - CYCLOSET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877708 VEROSCIENCE Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders Jun, 2030

(7 years from now)

US9895422 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders Jun, 2030

(7 years from now)

US9352025 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders Jun, 2030

(7 years from now)

US10688155 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders Jun, 2030

(7 years from now)

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Treatment: Treatment of type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue wherein the combined therapeutic effect is greater than the additive effect of administering each agent alone; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 11 and wherein the effects are as recited in claim 11; adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 2 and wherein the effects are as recited in claim 2; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 16-19 and wherein the effects are as recited in claims 16-19; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 12 and wherein the effects are as recited in claim 12; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 9 and wherein the effects are as recited in claim 9; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 8 and wherein the effects are as recited in claim 8; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 14 and wherein the effects are as recited in claim 14; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 3-7 and wherein the effects are as recited in claims 3-7; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1-5 and wherein the effects are as recited in claims 1-5; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 7 and wherein the effects are as recited in claim 7; adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 14-15 and wherein the effects are as recited in claims 14-15; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 9 and wherein the effects are as recited in claim 9; adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 16-18 and wherein the effects are as recited in claims 16-18; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 10 and wherein the effects are as recited in claim 10; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 6 and wherein the effects are as recited in claim 6; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 19 and wherein the effects are as recited in claim 19; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 12 and wherein the effects are as recited in claim 12; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 10; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 19 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 16 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 2 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 30 wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 27 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 17 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 15 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 28 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine meylate and a first-phase insulin secretagogue as recited in claims 1 and 3 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 8 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 5 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 11; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1, 17 and 18 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 13; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 22 wherein the effects are as recited in claim 22; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 24 and wherein the effects are as recited in claim 22; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 29 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 6 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 26 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 4 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 7 and wherein the effects are as recited in claim 1; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 25 and wherein the effects are as recited in claim 22; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 9; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 23 and wherein the effects are as recited in claim 22; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 56 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 31 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 44 and wherein the effects are as recited in claims 44 and 54; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 50 wherein the effects are as recited in said claims; adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 42 and wherein the effects are as recited in claim 42; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 44 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 49 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 45 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 34 wherein the effects are as recited in said claims; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 51 wherein the effects are as recited in said claims; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 32 wherein the effects are as recited in said claims; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 38 and wherein the effects are as recited claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 39 and wherein the effects are as recited in claim 26; once daily topical treatment of persistent facial erythema associated with rosacea in adults; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 36 wherein the effects are as recited in said claims; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 48 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 33 wherein the effects are as recited in claims; adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 42 and 43 wherein the effects are as recited in claim 42; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 47 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 40 and wherein the effects are as recited in claim 26; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 57 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 46 and wherein the effects are as recited in claim 44; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 52 wherein the effects are as recited in said claims

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.8MG BASE TABLET;ORAL Prescription

43. Drug name - DEXILANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food Mar, 2030

(7 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food Sep, 2030

(7 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; healing of all grades of erosive esophagitis (ee) for up to 8 weeks; maintain healing of erosive esophagitis (ee) for up to 6 months

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE, DELAYED RELEASE;ORAL Prescription
60MG CAPSULE, DELAYED RELEASE;ORAL Prescription

44. Drug name - DEXTENZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8563027 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs Feb, 2030

(7 years from now)

US8409606 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs May, 2030

(7 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery

Dosage: INSERT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.4MG INSERT;OPHTHALMIC Prescription

45. Drug name - DSUVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8574189 ACELRX PHARMS Storage and dispensing devices for administration of oral transmucosal dosage forms Mar, 2030

(7 years from now)

US10896751 ACELRX PHARMS Storage and dispensing devices for administration of oral transmucosal dosage forms Mar, 2030

(7 years from now)

US8202535 ACELRX PHARMS Small-volume oral transmucosal dosage forms Oct, 2030

(8 years from now)

US8865743 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain Oct, 2030

(8 years from now)

Drugs and Companies using SUFENTANIL CITRATE ingredient

Treatment: Treatment of acute pain

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 0.03MG BASE TABLET;SUBLINGUAL Prescription

46. Drug name - EDARBYCLOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9169238 ARBOR PHARMS LLC Solid pharmaceutical composition Feb, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 40MG MEDOXOMIL;12.5MG TABLET;ORAL Prescription
EQ 40MG MEDOXOMIL;25MG TABLET;ORAL Prescription

47. Drug name - ELLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10159681 LAB HRA PHARMA Method for on-demand contraception Apr, 2030

(7 years from now)

US10772897 LAB HRA PHARMA Method for on-demand contraception Apr, 2030

(7 years from now)

US9283233 LAB HRA PHARMA Method for on-demand contraception Apr, 2030

(7 years from now)

US8512745 LAB HRA PHARMA Ulipristal acetate tablets Jun, 2030

(7 years from now)

US8426392 LAB HRA PHARMA Method for providing emergency contraception Jun, 2030

(7 years from now)

US8962603 LAB HRA PHARMA Method for post coital contraception in overweight or obese female subjects using ulipristal acetate Jun, 2030

(7 years from now)

Drugs and Companies using ULIPRISTAL ACETATE ingredient

Treatment: A method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse; A method for contraception, the method comprising administering a tablet comprising 20 mg to 30 mg of ulipristal acetate to a woman within 120 hours after an unprotected intercourse; Method for contraception to a woman comprising administering to the woman 30mg of ulipristal acetate more than 72 hours and up to 120 hours after an unprotected intercourse; Ella is a progesterone agonist/antagonist emergency contraception indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella can be taken with or without food; Method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of 25 to 29.99

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET;ORAL Prescription

48. Drug name - ENTEREG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946262 CUBIST PHARMS Methods of preventing and treating gastrointestinal dysfunction Feb, 2030

(7 years from now)

Drugs and Companies using ALVIMOPAN ingredient

Treatment: A method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
12MG CAPSULE;ORAL Prescription

49. Drug name - EPCLUSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(8 years from now)

CN105085592A GILEAD SCIENCES INC N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof
May, 2030

(7 years from now)

CN102459299A GILEAD SCIENCES INC N- [ (2 ' R) -2 ' -Deoxy-2 ' - Fluoro-2'-Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine-1-Methylethyl Ester Process For Its Production
May, 2030

(7 years from now)

CN105085592B GILEAD SCIENCES INC N - [(2 ' R) - 2 ' - Deoxy-2 ' - Fluorine-2 ' - Methyl-Beta-Phenyl-5 ' - Uridine Acyl] -L - Lactamine 1-Methyl Ethyl Ester And Its Preparation Method
May, 2030

(7 years from now)

CN102459299B GILEAD SCIENCES INC N- [ (2 ' R) -2 ' -Deoxy-2 ' -Fluoro-2 ' -Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine 1-Methylethyl Ester And Process For Its Production
May, 2030

(7 years from now)

IN346815B GILEAD SCIENCES INC N-[ (2&Amp;Apos;R) -2&Amp;Apos; Deoxy-2&Amp;Apos;- Fluoro-2&Amp;Apos;-Methyl-Pphenyl- 5&Amp;Apos;-Uridylyl] -L-Alanine 1- Methylethyl Ester And Process For Its Production
May, 2030

(7 years from now)

EP2913337A1 GILEAD SCIENCES INC Process For The Production Of Sofosbuvir
May, 2030

(7 years from now)

EP3321275B1 GILEAD SCIENCES INC Crystalline Form Of Sofosbuvir
May, 2030

(7 years from now)

EP2432792A1 GILEAD SCIENCES INC And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester
May, 2030

(7 years from now)

EP2913337B1 GILEAD SCIENCES INC Process For The Production Of Sofosbuvir
May, 2030

(7 years from now)

EP3321275A1 GILEAD SCIENCES INC Crystalline Form Of Sofosbuvir
May, 2030

(7 years from now)

EP2432792B1 GILEAD SCIENCES INC And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester
May, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;37.5MG/PACKET PELLETS;ORAL Prescription
200MG;50MG/PACKET PELLETS;ORAL Prescription

50. Drug name - ERLEADA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8445507 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Sep, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription

51. Drug name - ESBRIET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318780 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

US7910610 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

US8754109 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450 Jan, 2030

(7 years from now)

US8648098 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450 Jan, 2030

(7 years from now)

US8013002 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

US8084475 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450 Jan, 2030

(7 years from now)

US7816383 GENENTECH INC Methods of administering pirfenidone therapy Jan, 2030

(7 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Treatment: Administering pirfenidone while avoiding concomitant use of a cyp1a2 inhibitor that is a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme selected from cyp2c9, cyp2c19, and cyp2d6; discontinuing use of a cyp1a2 inhibitor that is a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme selected from cyp2c9, cyp2c19, and cyp2d6 and then administering pirfenidone; Administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; discontinuing administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone and then administering pirfenidone; Administering pirfenidone while avoiding concomitant administration of a strong inducer of cyp1a2, including cigarette smoke, to avoid reduced pirfenidone efficacy; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing a strong cyp1a2 inducer; Administering pirfenidone concurrently with fluvoxamine, the pirfenidone at a dose of about 801 mg/day to reduce drug interactions with fluvoxamine; modifying pirfenidone administration from a dose of about 2400 mg/day downward by about 1600 mg/day while co-administering fluvoxamine to reduce drug interactions with fluvoxamine; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing or avoiding another strong cyp1a2 inducer; Method for administering pirfenidone to reduce drug interactions with fluvoxamine

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
267MG CAPSULE;ORAL Prescription

52. Drug name - EUCRISA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168614 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents Jan, 2030

(7 years from now)

US8168614

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents Jul, 2030

(7 years from now)

Drugs and Companies using CRISABOROLE ingredient

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% OINTMENT;TOPICAL Prescription

53. Drug name - EVOMELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020363 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same May, 2030

(7 years from now)

US10864183 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same May, 2030

(7 years from now)

US10940128 ACROTECH Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same Jun, 2030

(7 years from now)

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE/VIAL POWDER;INTRAVENOUS Prescription

54. Drug name - EXEM FOAM KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034300 GISKIT Composition and method for medical imaging of body cavities Oct, 2030

(8 years from now)

Drugs and Companies using AIR POLYMER-TYPE A ingredient

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
10ML FOAM;INTRAUTERINE Prescription

55. Drug name - FABIOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568859 MAYNE PHARMA Topical foam composition Feb, 2030

(7 years from now)

US10688071 MAYNE PHARMA Topical foam composition Feb, 2030

(7 years from now)

US8808716 MAYNE PHARMA Topical foam composition Feb, 2030

(7 years from now)

Drugs and Companies using TAZAROTENE ingredient

Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.1% AEROSOL, FOAM;TOPICAL Prescription

56. Drug name - FANAPT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9157121 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene Apr, 2030

(7 years from now)

US8652776 VANDA PHARMS INC Prediction of QT prolongation based on SNP genotype Aug, 2030

(7 years from now)

US8999638 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene Oct, 2030

(8 years from now)

US9074255 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation Dec, 2030

(8 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone; Dosage modification to reduce the risk associated with qt prolongation not induced by other drugs during treatment with iloperidone

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
6MG TABLET;ORAL Prescription
8MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

57. Drug name - FARXIGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder Jan, 2030

(7 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof May, 2030

(7 years from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

58. Drug name - FLOLIPID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597289 TCG FLUENT PHARMA Liquid oral simvastatin compositions Feb, 2030

(7 years from now)

Drugs and Companies using SIMVASTATIN ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
20MG/5ML SUSPENSION;ORAL Prescription
40MG/5ML SUSPENSION;ORAL Prescription

59. Drug name - FOSRENOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9023397 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds Dec, 2030

(8 years from now)

US8980327 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds Dec, 2030

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE POWDER;ORAL Prescription
EQ 750MG BASE POWDER;ORAL Prescription

60. Drug name - FYARRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206887 AADI Prion free nanoparticle compositions and methods of making thereof Apr, 2030

(7 years from now)

Drugs and Companies using SIROLIMUS ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

61. Drug name - GEMTESA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8247415 UROVANT Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
Dec, 2030

(8 years from now)

Drugs and Companies using VIBEGRON ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
75MG TABLET;ORAL Prescription

62. Drug name - GENOSYL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103669 VERO BIOTECH Nitric oxide therapies Jun, 2030

(7 years from now)

US8607785 VERO BIOTECH Systems and devices for generating nitric oxide Jul, 2030

(7 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
800PPM GAS;INHALATION Prescription

63. Drug name - GENVOYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8148374

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics Mar, 2030

(7 years from now)

US9891239

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics Mar, 2030

(7 years from now)

US8633219 GILEAD SCIENCES INC Combination therapy Apr, 2030

(7 years from now)

US8633219

(Pediatric)

GILEAD SCIENCES INC Combination therapy Oct, 2030

(8 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;150MG;200MG;EQ 10MG BASE TABLET;ORAL Prescription

64. Drug name - GILOTRIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8426586

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds Apr, 2030

(7 years from now)

US8545884

(Pediatric)

BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992 Jun, 2030

(7 years from now)

US10004743 BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient Jul, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription

65. Drug name - GIMOTI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8334281 EVOKE PHARMA INC Nasal formulations of metoclopramide May, 2030

(7 years from now)

Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient

Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 15MG BASE/SPRAY SPRAY, METERED;NASAL Prescription

66. Drug name - GOCOVRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741343 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

US9867792 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

US9867791 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

US9877933 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

US9867793 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

US11197835 ADAMAS PHARMA Method of administering amantadine prior to a sleep period Dec, 2030

(8 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 68.5MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 137MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

67. Drug name - HARVONI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8822430 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8088368 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(8 years from now)

CN104211689B GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN106588890B GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN104211689A GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN104230900B GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN102596936A GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN103977406B GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN104016971A GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN104211713B GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN102596936B GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN104211713A GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

CN106588890A GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN104016971B GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN103977406A GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN104230900A GILEAD SCIENCES INC Antiviral Compound
May, 2030

(7 years from now)

CN105085592B GILEAD SCIENCES INC N - [(2 ' R) - 2 ' - Deoxy-2 ' - Fluorine-2 ' - Methyl-Beta-Phenyl-5 ' - Uridine Acyl] -L - Lactamine 1-Methyl Ethyl Ester And Its Preparation Method
May, 2030

(7 years from now)

CN102459299A GILEAD SCIENCES INC N- [ (2 ' R) -2 ' -Deoxy-2 ' - Fluoro-2'-Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine-1-Methylethyl Ester Process For Its Production
May, 2030

(7 years from now)

CN102459299B GILEAD SCIENCES INC N- [ (2 ' R) -2 ' -Deoxy-2 ' -Fluoro-2 ' -Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine 1-Methylethyl Ester And Process For Its Production
May, 2030

(7 years from now)

CN105085592A GILEAD SCIENCES INC N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof
May, 2030

(7 years from now)

IN346815B GILEAD SCIENCES INC N-[ (2&Amp;Apos;R) -2&Amp;Apos; Deoxy-2&Amp;Apos;- Fluoro-2&Amp;Apos;-Methyl-Pphenyl- 5&Amp;Apos;-Uridylyl] -L-Alanine 1- Methylethyl Ester And Process For Its Production
May, 2030

(7 years from now)

EP2873665A1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP3309157A1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP2873665B1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP3002281B1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP3309157B1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP3002281A1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP2430014B1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP2430014A1 GILEAD SCIENCES INC Antiviral Compounds
May, 2030

(7 years from now)

EP2913337A1 GILEAD SCIENCES INC Process For The Production Of Sofosbuvir
May, 2030

(7 years from now)

EP3321275B1 GILEAD SCIENCES INC Crystalline Form Of Sofosbuvir
May, 2030

(7 years from now)

EP2432792A1 GILEAD SCIENCES INC And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester
May, 2030

(7 years from now)

EP2913337B1 GILEAD SCIENCES INC Process For The Production Of Sofosbuvir
May, 2030

(7 years from now)

EP3321275A1 GILEAD SCIENCES INC Crystalline Form Of Sofosbuvir
May, 2030

(7 years from now)

EP2432792B1 GILEAD SCIENCES INC And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester
May, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511056 GILEAD SCIENCES INC Antiviral compounds May, 2030

(7 years from now)

US8273341 GILEAD SCIENCES INC Antiviral compounds May, 2030

(7 years from now)

US8841278 GILEAD SCIENCES INC Antiviral compounds May, 2030

(7 years from now)

US8822430

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds Nov, 2030

(8 years from now)

US8841278

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds Nov, 2030

(8 years from now)

US9511056

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds Nov, 2030

(8 years from now)

US8088368

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds Nov, 2030

(8 years from now)

US8273341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds Nov, 2030

(8 years from now)

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
33.75MG;150MG/PACKET PELLETS;ORAL Prescription
45MG;200MG/PACKET PELLETS;ORAL Prescription

68. Drug name - IBSRELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006281 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders May, 2030

(7 years from now)

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription

69. Drug name - IDHIFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 CELGENE CORP Methods and compositions for cell-proliferation-related disorders Jun, 2030

(7 years from now)

Drugs and Companies using ENASIDENIB MESYLATE ingredient

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

70. Drug name - ILEVRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662398 NOVARTIS Carboxylvinyl polymer-containing nanoparticle suspensions Dec, 2030

(8 years from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.3% SUSPENSION/DROPS;OPHTHALMIC Prescription

71. Drug name - IMPLANON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9757552 ORGANON Applicator for inserting an implant Jul, 2030

(7 years from now)

Drugs and Companies using ETONOGESTREL ingredient

Treatment: Prevention of pregnancy

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage
Strength Dosage Availability
68MG/IMPLANT IMPLANT;IMPLANTATION Prescription

72. Drug name - IMPOYZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10064875 PRIMUS PHARMS Topical formulations comprising a steroid Aug, 2030

(7 years from now)

US9956231 PRIMUS PHARMS Topical formulations comprising a steroid Aug, 2030

(7 years from now)

US10588914 PRIMUS PHARMS Topical formulations comprising a steroid Aug, 2030

(7 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Treatment: Treatment of moderate plaque psoriasis; treatment of plaque psoriasis; psoriasis; treatment of plaque psoriasis in patients 18 years of age or older; twice daily topical treatment of moderate to severe plaque psoriasis.; Treatment of moderate plaque psoriasis; treatment of plaque psoriasis in patients 18 years of age or older; psoriasis; twice daily topical treatment of moderate to severe plaque psoriasis.; treatment of plaque psoriasis; plaque psoriasis; Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.025% CREAM;TOPICAL Prescription

73. Drug name - INCRUSE ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXO GRP ENGLAND Manifold for use in medicament dispenser Mar, 2030

(7 years from now)

US8746242 GLAXO GRP ENGLAND Medicament dispenser Oct, 2030

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 62.5MCG BASE/INH POWDER;INHALATION Prescription

74. Drug name - INLYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8791140 PF PRISM CV Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Dec, 2030

(8 years from now)

Drugs and Companies using AXITINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

75. Drug name - INQOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8268800 OTSUKA Certain compounds, compositions and methods
Aug, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
100MG;35MG TABLET;ORAL Prescription

76. Drug name - ISENTRESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649311 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor Oct, 2030

(8 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE TABLET;ORAL Prescription
EQ 600MG BASE TABLET;ORAL Prescription

77. Drug name - JATENZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10617696 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11179403 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same Apr, 2030

(7 years from now)

US8778916 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same Apr, 2030

(7 years from now)

US10543219 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same Apr, 2030

(7 years from now)

US8492369 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same Dec, 2030

(8 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
158MG CAPSULE;ORAL Prescription
198MG CAPSULE;ORAL Prescription
237MG CAPSULE;ORAL Prescription

78. Drug name - JENTADUETO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation May, 2030

(7 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor Jun, 2030

(7 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET;ORAL Prescription
2.5MG;500MG TABLET;ORAL Prescription
2.5MG;850MG TABLET;ORAL Prescription

79. Drug name - JENTADUETO XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation May, 2030

(7 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

80. Drug name - JEVTANA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583110 SANOFI AVENTIS US Antitumoral use of cabazitaxel Oct, 2030

(8 years from now)

US10716777 SANOFI AVENTIS US Antitumoral use of cabazitaxel Oct, 2030

(8 years from now)

US8927592 SANOFI AVENTIS US Antitumoral use of cabazitaxel Oct, 2030

(8 years from now)

Drugs and Companies using CABAZITAXEL ingredient

Treatment: Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist; Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
60MG/1.5ML (40MG/ML) SOLUTION;INTRAVENOUS Prescription

81. Drug name - JUBLIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10105444 BAUSCH Compositions and methods for treating diseases of the nail Jul, 2030

(7 years from now)

US9861698 BAUSCH Compositions and methods for treating diseases of the nail Jul, 2030

(7 years from now)

US8039494 BAUSCH Compositions and methods for treating diseases of the nail Jul, 2030

(7 years from now)

US8486978 BAUSCH Compositions and methods for treating diseases of the nail Oct, 2030

(8 years from now)

US9302009 BAUSCH Compositions and methods for treating diseases of the nail Oct, 2030

(8 years from now)

Drugs and Companies using EFINACONAZOLE ingredient

Treatment: Antimycotic uses, specifically treatment of onychomycosis

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
10% SOLUTION;TOPICAL Prescription

82. Drug name - JYNARQUE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905694 OTSUKA Pharmaceutical solid preparation comprising benzazepines and production method thereof Apr, 2030

(7 years from now)

Drugs and Companies using TOLVAPTAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription
45MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription

83. Drug name - KENGREAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427448 CHIESI Methods of treating, reducing the incidence of, and/or preventing ischemic events Nov, 2030

(8 years from now)

Drugs and Companies using CANGRELOR ingredient

Treatment: Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/VIAL POWDER;INTRAVENOUS Prescription

84. Drug name - KIMYRSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin Apr, 2030

(7 years from now)

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 1.2GM BASE/VIAL POWDER;INTRAVENOUS Prescription

85. Drug name - KISQALI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

86. Drug name - KISQALI FEMARA CO-PACK (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
2.5MG;EQ 200MG BASE TABLET;ORAL Prescription

87. Drug name - KOVANAZE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9308191 ST RENATUS Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration Apr, 2030

(7 years from now)

US8580282 ST RENATUS Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration Apr, 2030

(7 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE ingredient

Treatment: Method of anesthetizing at least a portion of the maxillary dental arch

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.1MG/SPRAY;6MG/SPRAY SPRAY, METERED;NASAL Prescription

88. Drug name - KYBELLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500214 KYTHERA BIOPHARMS Formulations of deoxycholic acid and salts thereof Mar, 2030

(7 years from now)

US8101593 KYTHERA BIOPHARMS Formulations of deoxycholic acid and salts thereof Mar, 2030

(7 years from now)

US8367649 KYTHERA BIOPHARMS Formulations of deoxycholic acid and salts thereof Mar, 2030

(7 years from now)

US8653058 KYTHERA BIOPHARMS Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits Mar, 2030

(7 years from now)

Drugs and Companies using DEOXYCHOLIC ACID ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
20MG/2ML (10MG/ML) SOLUTION;SUBCUTANEOUS Prescription

89. Drug name - KYNMOBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9044475 SUNOVION PHARMS INC Sublingual apomorphine Jun, 2030

(7 years from now)

US9669021 SUNOVION PHARMS INC Sublingual apomorphine Jun, 2030

(7 years from now)

US9669019 SUNOVION PHARMS INC Sublingual apomorphine Jun, 2030

(7 years from now)

US9283219 SUNOVION PHARMS INC Sublingual films Jun, 2030

(7 years from now)

US10420763 SUNOVION PHARMS INC Sublingual apomorphine Jun, 2030

(7 years from now)

US9326981 SUNOVION PHARMS INC Sublingual apomorphine Jun, 2030

(7 years from now)

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
10MG FILM;SUBLINGUAL Prescription
15MG FILM;SUBLINGUAL Prescription
20MG FILM;SUBLINGUAL Prescription
25MG FILM;SUBLINGUAL Prescription
30MG FILM;SUBLINGUAL Prescription

90. Drug name - LONHALA MAGNAIR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789270 SUNOVION RESP Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized Oct, 2030

(8 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
25MCG/ML SOLUTION;INHALATION Prescription

91. Drug name - LUMIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259425 BAUSCH AND LOMB INC Compositions and methods for eye whitening Jul, 2030

(7 years from now)

US8293742 BAUSCH AND LOMB INC Preferential vasoconstriction compositions and methods of use Jul, 2030

(7 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.025% SOLUTION/DROPS;OPHTHALMIC Over the counter

92. Drug name - MAVYRET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028937 ABBVIE INC Anti-viral compounds Jun, 2030

(7 years from now)

US10039754 ABBVIE INC Anti-viral compounds Jun, 2030

(7 years from now)

US9586978 ABBVIE INC Anti-viral compounds Nov, 2030

(8 years from now)

US10028937

(Pediatric)

ABBVIE INC Anti-viral compounds Dec, 2030

(8 years from now)

US10039754

(Pediatric)

ABBVIE INC Anti-viral compounds Dec, 2030

(8 years from now)

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG;40MG TABLET;ORAL Prescription

93. Drug name - MAYZENT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441 NOVARTIS Dosage regimen of an S1P receptor agonist Nov, 2030

(8 years from now)

Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription
EQ 2MG BASE TABLET;ORAL Prescription

94. Drug name - MEKINIST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(8 years from now)

CN102655753B NOVARTIS Combined Medicine
Oct, 2030

(8 years from now)

CN102655753A NOVARTIS Combination
Oct, 2030

(8 years from now)

EP2488033A1 NOVARTIS Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
Oct, 2030

(8 years from now)

EP2488033A4 NOVARTIS Combination
Oct, 2030

(8 years from now)

EP2488033B1 NOVARTIS Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
Oct, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors Oct, 2030

(8 years from now)

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG TABLET;ORAL Prescription
EQ 1MG TABLET;ORAL Discontinued
EQ 2MG TABLET;ORAL Prescription

95. Drug name - MEKTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors Aug, 2030

(7 years from now)

Drugs and Companies using BINIMETINIB ingredient

Treatment: Indicated in combination with encorafenib for the treatment of melanoma; Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET;ORAL Prescription

96. Drug name - MILPROSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580293 FERRING PHARMS INC Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof Jan, 2030

(7 years from now)

Drugs and Companies using PROGESTERONE ingredient

Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women

Dosage: SYSTEM;VAGINAL

More Information on Dosage
Strength Dosage Availability
1.78GM SYSTEM;VAGINAL Discontinued

97. Drug name - MINIVELLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8231906 NOVEN Transdermal estrogen device and delivery
Jul, 2030

(7 years from now)

Drugs and Companies using ESTRADIOL ingredient

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
0.025MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
0.0375MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
0.05MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
0.075MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
0.1MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription

98. Drug name - MULPLETA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8530668 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jan, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription

99. Drug name - MYOVIEW

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549999 GE HEALTHCARE Radiopharmaceutical composition Mar, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
N/A INJECTABLE;INJECTION Prescription

100. Drug name - MYRBETRIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842780

(Pediatric)

APGDI Pharmaceutical composition for modified release Mar, 2030

(7 years from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET, EXTENDED RELEASE;ORAL Prescription
50MG TABLET, EXTENDED RELEASE;ORAL Prescription

101. Drug name - NERLYNX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7399865 PUMA BIOTECH Protein tyrosine kinase enzyme inhibitors
Dec, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211291 PUMA BIOTECH Treatment regimen utilizing neratinib for breast cancer Mar, 2030

(7 years from now)

US8790708 PUMA BIOTECH Coated tablet formulations and uses thereof Nov, 2030

(8 years from now)

US8518446 PUMA BIOTECH Coated tablet formulations and uses thereof Nov, 2030

(8 years from now)

Drugs and Companies using NERATINIB MALEATE ingredient

Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE TABLET;ORAL Prescription

102. Drug name - NEUPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130589 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine Dec, 2030

(8 years from now)

US10350174 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine Dec, 2030

(8 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
1MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
2MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
3MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
4MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
6MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
8MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription

103. Drug name - NOCDURNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9974826 FERRING PHARMS INC Methods comprising desmopressin Apr, 2030

(7 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: Treatment of nocturia due to nocturnal polyuria in adults; treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
0.0277MG TABLET;SUBLINGUAL Prescription
0.0553MG TABLET;SUBLINGUAL Prescription

104. Drug name - NOCTIVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539302 SERENITY PHARMS LLC Safe desmopressin administration Jun, 2030

(7 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.00083MG/SPRAY SPRAY, METERED;NASAL Discontinued
0.00166MG/SPRAY SPRAY, METERED;NASAL Discontinued

105. Drug name - NUBEQA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(8 years from now)

US10711013 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(8 years from now)

US11046713 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(8 years from now)

US9657003 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(8 years from now)

CN102596910A BAYER HEALTHCARE Androgen Receptor Modulator Compounds
Oct, 2030

(8 years from now)

CN105061313A BAYER HEALTHCARE Androgen Receptor Regulation Compound
Oct, 2030

(8 years from now)

CN105061313B BAYER HEALTHCARE Androgen Receptor Modulator Compounds
Oct, 2030

(8 years from now)

CN102596910B BAYER HEALTHCARE Androgen Receptor Modulator Compounds
Oct, 2030

(8 years from now)

IN304033B BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

IN201200848P2 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP3056485B1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP3369732B1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP3369732A1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP3056485A1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP2493858B1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

EP2493858A1 BAYER HEALTHCARE Androgen Receptor Modulating Compounds
Oct, 2030

(8 years from now)

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription

106. Drug name - NUPLAZID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601740 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Apr, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 17MG BASE TABLET;ORAL Discontinued

107. Drug name - NUZYRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8383610 PARATEK PHARMS INC Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Sep, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription

108. Drug name - OLUMIANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8158616 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Jun, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription

109. Drug name - ONGENTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583130 NEUROCRINE Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof Mar, 2030

(7 years from now)

US10071085 NEUROCRINE Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof Mar, 2030

(7 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: Method of treating parkinson's disease

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription
50MG CAPSULE;ORAL Prescription

110. Drug name - ONPATTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802644 ALNYLAM PHARMS INC Lipid formulation Oct, 2030

(8 years from now)

US8158601 ALNYLAM PHARMS INC Lipid formulation Nov, 2030

(8 years from now)

Drugs and Companies using PATISIRAN SODIUM ingredient

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

111. Drug name - ONUREG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846628 CELGENE CORP Oral formulations of cytidine analogs and methods of use thereof Jun, 2030

(7 years from now)

Drugs and Companies using AZACITIDINE ingredient

Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

112. Drug name - ONZETRA XSAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8899229 CURRAX Powder delivery devices Aug, 2030

(7 years from now)

US9649456 CURRAX Nasal administration Oct, 2030

(8 years from now)

US8978647 CURRAX Nasal delivery Dec, 2030

(8 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Acute treatment of migraine; treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE POWDER;NASAL Prescription

113. Drug name - ORBACTIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin Apr, 2030

(7 years from now)

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

Treatment: Treatment of bacterial skin and skin structure infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 400MG BASE/VIAL POWDER;INTRAVENOUS Prescription

114. Drug name - ORENITRAM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410169 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs Feb, 2030

(7 years from now)

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.125MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 0.25MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

115. Drug name - ORKAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8507534 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
Sep, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716338 VERTEX PHARMS INC Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Sep, 2030

(7 years from now)

US8993600 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Dec, 2030

(8 years from now)

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using the dosage unit comprising lumacaftor as recited in claim 1 of us patent 8716338 and ivacaftor

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
125MG/PACKET;100MG/PACKET GRANULE;ORAL Prescription
188MG/PACKET;150MG/PACKET GRANULE;ORAL Prescription

116. Drug name - OSMOLEX ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252331 ADAMAS PHARMA Osmotic device containing amantadine and an osmotic salt Mar, 2030

(7 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 129MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 161MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
EQ 193MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 258MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

117. Drug name - OTIPRIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318817 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of otic disorders Apr, 2030

(7 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Treatment: Treatment of otic infection or inflammation

Dosage: INJECTABLE, SUSPENSION;OTIC

More Information on Dosage
Strength Dosage Availability
6% (60MG/ML) INJECTABLE, SUSPENSION;OTIC Prescription

118. Drug name - OTOVEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8932610 LABORATORIOS SALVAT Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation Mar, 2030

(7 years from now)

Drugs and Companies using CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE ingredient

Treatment: Treatment of acute otitis media

Dosage: SOLUTION/DROPS;OTIC

More Information on Dosage
Strength Dosage Availability
EQ 0.3% BASE;0.025% SOLUTION/DROPS;OTIC Prescription

119. Drug name - OTREXUP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421333 OTTER PHARMS Hazardous agent injection system Mar, 2030

(7 years from now)

US8945063 OTTER PHARMS Hazardous agent injection system Mar, 2030

(7 years from now)

US8579865 OTTER PHARMS Hazardous agent injection system Mar, 2030

(7 years from now)

US8480631 OTTER PHARMS Hazardous agent injection system Mar, 2030

(7 years from now)

Drugs and Companies using METHOTREXATE ingredient

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
7.5MG/0.4ML (7.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
10MG/0.4ML (10MG/0.4ML) SOLUTION;SUBCUTANEOUS Discontinued
12.5MG/0.4ML (12.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.4ML (15MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
17.5MG/0.4ML (17.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
20MG/0.4ML (20MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
22.5MG/0.4ML (22.5MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
25MG/0.4ML (25MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
15MG/0.6ML (15MG/0.6ML) SOLUTION;SUBCUTANEOUS Discontinued
17.5MG/0.7ML (17.5MG/0.7ML) SOLUTION;SUBCUTANEOUS Discontinued
20MG/0.8ML (20MG/0.8ML) SOLUTION;SUBCUTANEOUS Discontinued
22.5MG/0.9ML (22.5MG/0.9ML) SOLUTION;SUBCUTANEOUS Discontinued
25MG/ML (25MG/ML) SOLUTION;SUBCUTANEOUS Discontinued

120. Drug name - OXYCONTIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8894987 PURDUE PHARMA LP Tamper resistant dosage forms Mar, 2030

(7 years from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET, EXTENDED RELEASE;ORAL Prescription
15MG TABLET, EXTENDED RELEASE;ORAL Prescription
20MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription
40MG TABLET, EXTENDED RELEASE;ORAL Prescription
60MG TABLET, EXTENDED RELEASE;ORAL Prescription
80MG TABLET, EXTENDED RELEASE;ORAL Prescription

121. Drug name - PARSABIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9278995 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US9701712 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US8377880 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

CN102711789A KAI PHARMS INC Therapeutic Agents For Reducing Parathyroid Hormone Levels
Jul, 2030

(7 years from now)

CN102711789B KAI PHARMS INC Therapeutic Agents For Reducing Parathyroid Hormone Level
Jul, 2030

(7 years from now)

IN350519B KAI PHARMS INC Therapeutic Agents For Reducing Parathyroid Hormone Levels
Jul, 2030

(7 years from now)

IN201201196P1 KAI PHARMS INC Therapeutic Agents For Reducing Parathyroid Hormone Levels
Jul, 2030

(7 years from now)

EP3192520B1 KAI PHARMS INC Therapeutic Agents For Reducing Parathyroid Hormone Levels
Jul, 2030

(7 years from now)

EP3539555A1 KAI PHARMS INC Therapeutic Agents For Reducing Parathyroid Hormone Levels
Jul, 2030

(7 years from now)

EP3539555B1 KAI PHARMS INC Therapeutic Agents For Reducing Parathyroid Hormone Levels
Jul, 2030

(7 years from now)

EP3192520A1 KAI PHARMS INC Therapeutic Agents For Reducing Parathyroid Hormone Levels
Jul, 2030

(7 years from now)

EP2459208A4 KAI PHARMS INC Therapeutic Agents For Reducing Parathyroid Hormone Levels
Jul, 2030

(7 years from now)

EP2459208B1 KAI PHARMS INC Therapeutic Agents For Reducing Parathyroid Hormone Levels
Jul, 2030

(7 years from now)

EP2459208A2 KAI PHARMS INC Therapeutic Agents For Reducing Parathyroid Hormone Levels
Jul, 2030

(7 years from now)

Drugs and Companies using ETELCALCETIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION;INTRAVENOUS Prescription
5MG/ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription
10MG/2ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

122. Drug name - PENNSAID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546450 HORIZON Treatment of pain with topical diclofenac compounds Aug, 2030

(7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Combination use of topical diclofenac on the knee and administration of an oral nsaid.; use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% SOLUTION;TOPICAL Prescription

123. Drug name - PENNSAID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546450 NUVO PHARMS INC Treatment of pain with topical diclofenac compounds Aug, 2030

(7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Combination use of topical diclofenac on the knee and administration of an oral nsaid.; use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
1.5% SOLUTION;TOPICAL Discontinued

124. Drug name - PHOSLYRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8591938 FRESENIUS MEDCL Liquid compositions of calcium acetate Feb, 2030

(7 years from now)

Drugs and Companies using CALCIUM ACETATE ingredient

Treatment: Use of phoslyra for reduction of serum phosphorous in patients

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
667MG/5ML SOLUTION;ORAL Prescription

125. Drug name - PIQRAY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8227462 NOVARTIS Pyrrolidine-1,2-dicarboxamide derivatives
Sep, 2030

(7 years from now)

Drugs and Companies using ALPELISIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription

126. Drug name - POMALYST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993467 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione May, 2030

(7 years from now)

US10555939 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione May, 2030

(7 years from now)

US10555939

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione Nov, 2030

(8 years from now)

US9993467

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione Nov, 2030

(8 years from now)

Drugs and Companies using POMALIDOMIDE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
1MG CAPSULE;ORAL Prescription
2MG CAPSULE;ORAL Prescription
3MG CAPSULE;ORAL Prescription
4MG CAPSULE;ORAL Prescription

127. Drug name - PYLARIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8778305 PROGENICS PHARMS INC PSMA-binding agents and uses thereof
Sep, 2030

(7 years from now)

Drugs and Companies using PIFLUFOLASTAT F-18 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50ML (1-80mCi/ML) SOLUTION;INTRAVENOUS Prescription

128. Drug name - QBREXZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744105 JOURNEY Topical glycopyrrolate formulations Jul, 2030

(7 years from now)

Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 2.4% BASE CLOTH;TOPICAL Prescription

129. Drug name - QINLOCK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188113 DECIPHERA PHARMS Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jul, 2030

(7 years from now)

Drugs and Companies using RIPRETINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription

130. Drug name - QMIIZ ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545879 TERSERA Fast disintegrating compositions of meloxicam Aug, 2030

(7 years from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
7.5MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
15MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued

131. Drug name - QTERNMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616028 ASTRAZENECA AB Bilayer tablet formulations Nov, 2030

(8 years from now)

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

132. Drug name - QUTENZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8821920 AVERITAS Therapeutic patch for transdermal delivery of capsaicin Mar, 2030

(7 years from now)

Drugs and Companies using CAPSAICIN ingredient

Treatment: NA

Dosage: PATCH;TOPICAL

More Information on Dosage
Strength Dosage Availability
8% PATCH;TOPICAL Prescription

133. Drug name - QUZYTTIR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180090 JDP Non-sedating antihistamine injection formulations and methods of use thereof Feb, 2030

(7 years from now)

US9119771 JDP Non-sedating antihistamine injection formulations and methods of use thereof Feb, 2030

(7 years from now)

US8513259 JDP Non-sedating antihistamine injection formulations and methods of use thereof Feb, 2030

(7 years from now)

US8314083 JDP Non-sedating antihistamine injection formulations and methods of use thereof Feb, 2030

(7 years from now)

US8263581 JDP Non-sedating antihistamine injection formulations and methods of use thereof Feb, 2030

(7 years from now)

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Treatment: Treatment of acute urticaria; Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Method of treatment in patients with concomitant angioedema

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
10MG/ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription

134. Drug name - RAVICTI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183002 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Sep, 2030

(7 years from now)

US10045958 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Sep, 2030

(7 years from now)

US10183006 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Sep, 2030

(7 years from now)

US10183005 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Sep, 2030

(7 years from now)

US10668040 HORIZON THERAP Treatment of urea cycle disorders in neonates and infants Sep, 2030

(7 years from now)

US9962359 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Sep, 2030

(7 years from now)

US9999608 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Sep, 2030

(7 years from now)

US10045959 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Sep, 2030

(7 years from now)

US8642012 HORIZON THERAP Methods of treatment using ammonia-scavenging drugs Sep, 2030

(7 years from now)

US10183004 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Sep, 2030

(7 years from now)

US9561197 HORIZON THERAP Methods of therapeutic monitoring of phenylacetic acid prodrugs Sep, 2030

(7 years from now)

US10183003 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs Sep, 2030

(7 years from now)

Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient

Treatment: Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder

Dosage: LIQUID;ORAL

More Information on Dosage
Strength Dosage Availability
1.1GM/ML LIQUID;ORAL Prescription

135. Drug name - RELISTOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8247425 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Dec, 2030

(8 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
8MG/0.4ML (8MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
12MG/0.6ML (12MG/0.6ML) SOLUTION;SUBCUTANEOUS Prescription

136. Drug name - RENVELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9095509 GENZYME Sachet formulation for amine polymers Dec, 2030

(8 years from now)

Drugs and Companies using SEVELAMER CARBONATE ingredient

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
2.4GM/PACKET FOR SUSPENSION;ORAL Prescription
800MG/PACKET FOR SUSPENSION;ORAL Prescription

137. Drug name - RHOPRESSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10174017 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(7 years from now)

US10654844 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(7 years from now)

US8394826 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Nov, 2030

(8 years from now)

EP3354643B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP2424842B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP2424842A2 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3354643A1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3053913B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3053913A1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11028081 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease Jan, 2030

(7 years from now)

Drugs and Companies using NETARSUDIL MESYLATE ingredient

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.02% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

138. Drug name - RINVOQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47221 ABBVIE INC Tricyclic compounds
Dec, 2030

(8 years from now)

CN102711476A ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

CN109053742B ABBVIE INC Tricyclic Compounds
Dec, 2030

(8 years from now)

CN104370909A ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

CN104370909B ABBVIE INC Tricyclic Compounds
Dec, 2030

(8 years from now)

CN109053742A ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

CN102711476B ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

EP2506716A1 ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

EP2506716B1 ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

EP2506716A4 ABBVIE INC Novel Tricyclic Compounds
Dec, 2030

(8 years from now)

Drugs and Companies using UPADACITINIB ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription

139. Drug name - ROCKLATAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10174017 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(7 years from now)

US10654844 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Jan, 2030

(7 years from now)

US8394826 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease
Nov, 2030

(8 years from now)

EP3354643B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP2424842B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP2424842A2 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3354643A1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3053913B1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

EP3053913A1 AERIE PHARMS INC Dual Mechanism Inhibitors For The Treatment Of Disease
Jan, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11028081 AERIE PHARMS INC Dual mechanism inhibitors for the treatment of disease Jan, 2030

(7 years from now)

Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.005%;EQ 0.02% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

140. Drug name - RYDAPT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8575146 NOVARTIS Pharmaceutical uses of staurosporine derivatives Dec, 2030

(8 years from now)

Drugs and Companies using MIDOSTAURIN ingredient

Treatment: Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription

141. Drug name - SAFYRAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid Feb, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
3MG,N/A;0.03MG,N/A;0.451MG,0.451MG TABLET;ORAL Prescription

142. Drug name - SALONPAS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809615 HISAMITSU PHARM CO Adhesive preparation Jan, 2030

(7 years from now)